California State Teachers Retirement System bought a new position in Assembly Biosciences Inc (NASDAQ:ASMB) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 24,800 shares of the biopharmaceutical company’s stock, valued at approximately $512,000. California State Teachers Retirement System owned approximately 0.14% of Assembly Biosciences at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. Nationwide Fund Advisors bought a new position in Assembly Biosciences in the 2nd quarter worth about $161,000. Renaissance Technologies LLC bought a new position in shares of Assembly Biosciences during the first quarter valued at approximately $242,000. Parametric Portfolio Associates LLC boosted its stake in shares of Assembly Biosciences by 13.6% during the second quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 1,203 shares in the last quarter. Legal & General Group Plc bought a new position in shares of Assembly Biosciences during the second quarter valued at approximately $212,000. Finally, Wells Fargo & Company MN bought a new position in shares of Assembly Biosciences during the second quarter valued at approximately $213,000. Institutional investors and hedge funds own 62.09% of the company’s stock.
Assembly Biosciences Inc (NASDAQ:ASMB) opened at $44.10 on Thursday. Assembly Biosciences Inc has a one year low of $11.07 and a one year high of $52.37.
In other news, Director William R. Ringo sold 1,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $29.55, for a total transaction of $29,550.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last quarter, insiders have sold 3,000 shares of company stock worth $112,620. Insiders own 19.60% of the company’s stock.
ASMB has been the topic of a number of recent research reports. Chardan Capital reiterated a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th. BidaskClub upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research note on Friday, August 18th. Zacks Investment Research upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a research note on Wednesday, November 15th. Finally, Jefferies Group initiated coverage on shares of Assembly Biosciences in a research note on Wednesday, November 8th. They set a “buy” rating and a $50.00 price objective on the stock.
COPYRIGHT VIOLATION WARNING: “California State Teachers Retirement System Buys Shares of 24,800 Assembly Biosciences Inc (ASMB)” was originally reported by Zolmax and is the property of of Zolmax. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://zolmax.com/investing/california-state-teachers-retirement-system-buys-shares-of-24800-assembly-biosciences-inc-asmb/1829306.html.
Assembly Biosciences Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.